PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...
Treatment for stage 2 essential thrombocythemia is highly personalized. Not every patient requires medication right away, and ...
This report illustrates the relation between pseudohyperkalemia and thrombocytosis associated with myeloproliferative disease. Some laboratory studies on the mechanisms involved, serial observations ...
Consecutive patients discharged from the orthopaedic unit and admitted to the intensive rehabilitation unit of our hospital were identified. The ward uses multidisciplinary staff and a ...
John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.
John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease ...
Change in platelet counts was a common phenomenon after major joint surgery, and elevated PLTC occurred in about half of the patients who were admitted to the rehabilitation centre. Thrombocytosis was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results